DMS Imaging

Equities

DMSIM

BE0974289218

Healthcare Facilities & Services

Market Closed - Euronext Bruxelles Other stock markets 08:37:42 15/05/2024 pm IST			5-day change	1st Jan Change
0.0208 ^EUR	-0.95%		-13.33%	-11.49%

2023	DMS Imaging SA Reports Earnings Results for the Half Year Ended June 30, 2023	CI
2023	DMS Imaging SA Reports Earnings Results for the Full Year Ended December 31, 2022	CI

Biotech Tools Sa Reports Earnings Results for the Half Year Ended June 30, 2019

September 18, 2019 at 10:30 am IST

BioTech Tools SA announced earnings results for the half year ended June 30, 2019. For the half year, the company announced operating loss was EUR 7.809 million compared to EUR 5.356 million a year ago. Net loss was EUR 7.824 million compared to EUR 5.374 million a year ago.

Latest news about DMS Imaging

DMS Imaging SA Reports Earnings Results for the Half Year Ended June 30, 2023	22/23/22	CI
DMS Imaging SA Reports Earnings Results for the Full Year Ended December 31, 2022	28/23/28	CI
Diagnostic Medical Systems Unit Receives Order for Radiology Tables in Italy	12/23/12	MT
DMS Imaging SA Reports Earnings Results for the Half Year Ended June 30, 2022	01/22/01	CI
DMS Imaging SA Reports Earnings Results for the Full Year Ended December 31, 2021	01/22/01	CI
Diagnostic Medical Systems Takes Majority Stake In Asit Biotech	25/22/25	MT
Global markets live: Microsoft, Apple, The Boeing Company, AT&T, Activision Blizzard...	15/21/15
Asit Biotech S.A. Reports Earnings Results for the Half Year Ended June 30, 2020	30/20/30	CI
GLOBAL MARKETS LIVE: UBS eying new acquisition, Deutsche Bank’s suspicious transactions…	21/20/21
Asit Biotech S.A. Reports Earnings Results for the Full Year Ended December 31, 2019	07/20/07	CI
ASIT Biotech S.A. Announces Board Changes	20/20/20	CI
ASIT biotech Discloses Next Steps Following gp-ASIT+TM Phase III Results	20/19/20	CI
ASIT Biotech gp-ASIT+™ Phase III Trial in Grass Pollen Allergy Did Not Meet the Primary Endpoint	25/19/25	CI
ASIT Biotech Announces the Publication of a Mechanistic Study of Gp-ASIT+™, its Lead Product Candidate in Phase III	17/19/17	CI
ASIT Biotech Receives GMP Certification for Its Manufacturing Site in Liège, Belgium	07/19/07	CI
Biotech Tools Sa Reports Earnings Results for the Half Year Ended June 30, 2019	18/19/18	CI
ASIT biotech Confirms on Track for Phase III Results of gp-ASIT+™ in December 2019	05/19/05	CI
ASIT Biotech Raises EUR 9.225 Million in A Private Placement of Convertible Notes	22/19/22	CI
ASIT Biotech S.A. announced that it has received €9.225 million in funding	22/19/22	CI
ASIT Biotech S.A. announced a financing transaction	28/19/28	CI
ASIT Biotech Announces the Achievement of New Clinical and Corporate Development Milestones	02/19/02	CI
ASIT Biotech Appoints Frank Hazevoets as Chief Financial Officer	02/19/02	CI
ASIT Biotech S.A. Reports Earnings Results for the Full Year Ended December 31, 2018	02/19/02	CI
ASIT Biotech S.A. Provides Clinical Update	02/19/02	CI
ASIT Biotech S.A. Reveals the Mode of Action of its Immunotherapy Product for Allergic Rhinitis, gp-ASIT+™, in the Journal of Allergy and Clinical Immunology	05/19/05	CI

Chart DMS Imaging

Duration

Period

More charts

Company Profile

DMS Imaging specializes in the design and manufacture of imaging systems for digital and conventional radiology and bone densitometry. DMS Imaging offers radiology equipment (mobile radiology units, floating panel tables, mobile C-arm for operating room, etc.), ultrasound bone densitometers (for the reconstruction of bone microarchitecture), X-ray bone densitometers (for the measurement of bone density), etc. Net sales are distributed geographically as follows: Europe (61.3%), North and South America (18.4%), Asia (7.1%), Middle East (4.5%), Africa (3 .9%), Oceania (1.1%) and other (3.7%).

Sector

Healthcare Facilities & Services

Calendar

18/09/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Medical & Diagnostic Laboratories

	1st Jan change	Capi.
DMS IMAGING	-11.49%	33.67M
SONIC HEALTHCARE LIMITED	-15.96%	8.57B
RADNET, INC.	+67.50%	4.3B
DR. LAL PATHLABS LIMITED	-4.03%	2.46B
GUANGZHOU KINGMED DIAGNOSTICS GROUP CO., LTD.	-42.54%	2.31B
NEOGENOMICS, INC.	-6.49%	1.93B
FLEURY S.A.	-20.45%	1.53B
DIAN DIAGNOSTICS GROUP CO.,LTD.	-41.24%	1.2B
METROPOLIS HEALTHCARE LIMITED	+10.26%	1.14B
VIJAYA DIAGNOSTIC CENTRE LIMITED	+18.74%	986M

Medical & Diagnostic Laboratories